Hutch News
Results per Page:
New Scientific Publications
Each week, Fred Hutch librarians search PubMed and Web of Science to discover new papers published by Fred Hutch authors
Week of July 05, 2020
Immunotherapy trial in advanced bladder and other urinary tract cancers shows 'exciting' results
'Potentially practice-changing' data, presented at largest global cancer meeting, shows patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo
Study links common immune cell to failure of checkpoint inhibitors in lung cancer
New research suggests how to better predict which patients will respond to immunotherapy
New program to fast-track lung cancer research from lab to clinic
Patient-focused science at the heart of $13M National Cancer Institute grant
Cancer cells reconnect with their inner child to evade immunotherapy
Turning on an embryonic gene may help some tumors resist immune checkpoint inhibitors
The latest in prostate cancer research: 7 takeaways
7 takeaways from community symposium highlighting recent advances in prevention, screening and treatment
Dr. Cameron Howard Lee named 2019 Helen Hay Whitney Fellow
Biggins Lab postdoc will look at relationship between protein production and key cell-cycle checkpoint
Revealing a new way that cancer can evade immunotherapy — and, maybe, how to stop it
How a new technology solved a mystery and honors one man’s legacy
Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma
‘Incredibly big change’ in treatment of deadly skin cancer, new data show
For cancer patients with HIV, immunotherapy appears safe
Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials
The tumor microenvironment: How cancer fools healthy neighboring cells
‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients
Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy
Immune-based treatments move from the fringes to the spotlight
Triple therapy for rare skin cancer shows promise in small, early-stage trial
Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
Immunotherapy trial in rare skin cancer named one of 2016’s major advances in clinical cancer research and care
Study found long-lasting responses to immunotherapy drug in patients with Merkel cell carcinoma